Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
Cancer Medicine · 2026
DOI: 10.1002/cam4.72356 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Daniel J George und 8 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Abiraterone Acetate, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Nitriles. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astellas Pharma US, Pfizer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with chemotherapy‐ and androgen receptor pathway inhibitor (ARPI)‐naïve metastatic castration‐resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic health records (EHRs) is needed to confirm this finding.
Methods
This EHR‐based analysis (2014–2023) of the Flatiron Health database included patients with chemotherapy‐ and ARPI‐naïve mCRPC who initiated first‐line ARPI (abiraterone or enzalutamide). OS, treatment duration, and time to subsequent therapy were assessed. A subgroup analysis evaluated patients who received first‐line ARPI only with no subsequent treatments. Kaplan–Meier method and Cox proportional hazards models evaluated time‐to‐event outcomes. Stabilized inverse probability treatment weighting (sIPTW) adjusted for baseline differences.
Results
Among 2731 patients, 1316 received first‐line abiraterone and 1415 enzalutamide (median follow‐up: 21.8 and 23.2 months, respectively). sIPTW‐adjusted median OS (24.6 vs. 25.8 months; hazard ratio [HR] 1.13; 95% confidence interval [CI], 1.03–1.23), treatment duration (7.9 vs. 9.5 months; HR 1.21; 95% CI, 1.11–1.31), and time to subsequent therapy (14.7 vs. 17.9 months; HR 1.20; 95% CI, 1.08–1.32) were shorter with abiraterone versus enzalutamide. Among the 40% with no subsequent treatment ( n = 1102), sIPTW‐adjusted median OS (14.0 vs. 17.7 months; HR 1.32; 95% CI, 1.14–1.53), and treatment duration (7.5 vs. 10.6 months; HR 1.30; 95% CI, 1.12–1.50) were also shorter with abiraterone versus enzalutamide.
Conclusions
Using more detailed data abstraction, these results confirm prior claims‐based analyses showing that despite early use of subsequent therapy, first‐line abiraterone is associated with shorter OS versus enzalutamide in ARPI‐ and chemotherapy‐naïve mCRPC. Trial Registration Clinical Trial ID: NCT05968599
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Cancer Institute, Durham, North Carolina, USA.
- Pfizer Inc., New York, New York, USA.
- Astellas Pharma Inc., Northbrook, Illinois, USA.
- Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Durham VA Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Daniel J George, Stephen J Freedland
Förderung
- Astellas Pharma US
- Pfizer
Zitieren
APA
George, D. J., Ivanova, J. I., Touya, M., Thompson, B., Assayag, J., Li, B., Kountouris, N., Siu, G., & Freedland, S. J. (2026). Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database. Cancer Medicine. https://doi.org/10.1002/cam4.72356
Vancouver
George DJ, Ivanova JI, Touya M, Thompson B, Assayag J, Li B, et al. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database. Cancer Medicine. 2026. doi:10.1002/cam4.72356
BibTeX
@article{George2026,
author = {George, Daniel J and Ivanova, Jasmina I and Touya, Maëlys and Thompson, Betty and Assayag, Jonathan and Li, Benjamin and Kountouris, Nikolaos and Siu, Gordon and Freedland, Stephen J},
title = {Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72356}
}
EUVIMED